No insider purchase over the last 90 days. The latest, by 郭晓燕, was filed 04 Aug 2026.
Tianjin Lisheng Pharmaceutical Co.,Ltd.: what insiders have been doing
Tianjin Lisheng Pharmaceutical Co.,Ltd. is a listed company. Its directors and officers file their transactions with SSE / SZSE (CSRC). In the past year (8 November 2025 to 8 November 2026), 2 filings came from 1 insider.
Purchases and sales both appear in the filings: 1 purchase (1 insider, €19k) and 1 sale (1 insider, €19k). Taken together, the sales exceed the purchases by €352. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. At €19k, the sale published on 10 July 2026 by 郭晓燕 is the largest of the period. Those buying include 1 senior executive.
Compared with its exchange (533 companies, median 2 filings), a count of 2 filings is typical. Since 2026, the database holds 1 purchase and 1 sale by insiders of the company.
The clock since the last published purchase (4 August 2026) now reads 96 days.
These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- -3.1%Entry CN¥14.43 · Close at T+30 CN¥13.98
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
About Tianjin Lisheng Pharmaceutical Co.,Ltd.
力生制药 is a company focused on the research, development, and manufacturing of pharmaceutical products in China. It specializes in treatments for various diseases and medical conditions.